Cellectis (CLLS) Tops Q2 EPS by 1c

Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $3.47 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lantern Pharma (LTRN) files for 2.24M share offering by selling stockholders
• XORTX to voluntarily delist from TSX Venture Exchange